The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus.

Akyay OZ, Canturk Z, Selek A, Cetinarslan B, Tarkun İ, Cakmak Y, Baydemir C

Medicine1 Sept 2023Cited by 17 (Europe PMC)

PMID37773814PMCIDPMC10545322DOI10.1097/md.0000000000035394PepBankPUB-37773814

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with diabetes, exenatide reduced BMI more than insulin glargine.
In plain wordsIn postmenopausal women with diabetes, exenatide reduced BMI more than insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBMI
Study
n = 30
Comparator
Insulin glargine
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The body mass index significantly decreased in the exenatide group compared to the glargine group (P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty female patients with T2DM who were naive to insulin and incretin-based treatments, with spontaneous postmenopause, were randomized to exenatide or insulin glargine arms and were followed up for 24 weeks.
Report a problemFND-3777381401
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with diabetes, RANK levels decreased with exenatide.
In plain wordsIn postmenopausal women with diabetes, RANK levels decreased with exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseRANK
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Receptor activator of nuclear factor kappa-B (RANK) and RANK ligand (RANKL) levels were significantly decreased with exenatide treatment (P = .009 and P = .015, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty female patients with T2DM who were naive to insulin and incretin-based treatments, with spontaneous postmenopause, were randomized to exenatide or insulin glargine arms and were followed up for 24 weeks.
Report a problemFND-3777381402
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with diabetes, RANKL levels decreased with exenatide.
In plain wordsIn postmenopausal women with diabetes, RANKL levels decreased with exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseRANKL
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Receptor activator of nuclear factor kappa-B (RANK) and RANK ligand (RANKL) levels were significantly decreased with exenatide treatment (P = .009 and P = .015, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty female patients with T2DM who were naive to insulin and incretin-based treatments, with spontaneous postmenopause, were randomized to exenatide or insulin glargine arms and were followed up for 24 weeks.
Report a problemFND-3777381403
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with diabetes, OPG increased with exenatide.
In plain wordsIn postmenopausal women with diabetes, OPG increased with exenatide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseOPG
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Osteoprotegerin (OPG) level significantly increased with exenatide treatment (P = .02).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty female patients with T2DM who were naive to insulin and incretin-based treatments, with spontaneous postmenopause, were randomized to exenatide or insulin glargine arms and were followed up for 24 weeks.
Report a problemFND-3777381404
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with diabetes, bone mineral density did not change significantly with exenatide.
In plain wordsIn postmenopausal women with diabetes, bone density did not change significantly with exenatide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBone mineral density
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
No statistically significant difference was found between the pre- and posttreatment BMD, alkaline phosphatase, bone-specific alkaline phosphatase, and type 1 crosslinked N-telopeptide levels in both treatment arms.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty female patients with T2DM who were naive to insulin and incretin-based treatments, with spontaneous postmenopause, were randomized to exenatide or insulin glargine arms and were followed up for 24 weeks.
Report a problemFND-3777381405
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with diabetes, alkaline phosphatase did not change significantly with exenatide.
In plain wordsIn postmenopausal women with diabetes, alkaline phosphatase did not change significantly with exenatide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAlkaline phosphatase
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
No statistically significant difference was found between the pre- and posttreatment BMD, alkaline phosphatase, bone-specific alkaline phosphatase, and type 1 crosslinked N-telopeptide levels in both treatment arms.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty female patients with T2DM who were naive to insulin and incretin-based treatments, with spontaneous postmenopause, were randomized to exenatide or insulin glargine arms and were followed up for 24 weeks.
Report a problemFND-3777381406
07HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with diabetes, bone-specific alkaline phosphatase did not change significantly with exenatide.
In plain wordsIn postmenopausal women with diabetes, bone-specific alkaline phosphatase did not change significantly with exenatide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBone-specific alkaline phosphatase
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
No statistically significant difference was found between the pre- and posttreatment BMD, alkaline phosphatase, bone-specific alkaline phosphatase, and type 1 crosslinked N-telopeptide levels in both treatment arms.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty female patients with T2DM who were naive to insulin and incretin-based treatments, with spontaneous postmenopause, were randomized to exenatide or insulin glargine arms and were followed up for 24 weeks.
Report a problemFND-3777381407
08HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with diabetes, type 1 crosslinked N-telopeptide did not change significantly with exenatide.
In plain wordsIn postmenopausal women with diabetes, type 1 crosslinked N-telopeptide did not change significantly with exenatide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeType 1 crosslinked N-telopeptide
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
No statistically significant difference was found between the pre- and posttreatment BMD, alkaline phosphatase, bone-specific alkaline phosphatase, and type 1 crosslinked N-telopeptide levels in both treatment arms.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty female patients with T2DM who were naive to insulin and incretin-based treatments, with spontaneous postmenopause, were randomized to exenatide or insulin glargine arms and were followed up for 24 weeks.
Report a problemFND-3777381408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.